NEXTBio Capital Management LP 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
NEXTBio Capital Management LP disclosed 23 US equity positions worth $170.5m in its Q4 2025 13F filing. The largest position was 430 at 13.1% of the reported book, followed by PTGX and VOR.
What did NEXTBio Capital Management LP own in Q4 2025? Top 23 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | 430 TERNS PHARMACEUTICALS INC | 13.1% | $22.3m | 551,190 | – | ||
| 2 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 11.8% | $20.1m | 229,619 | – | |
| 3 | VOR VOR BIOPHARMA INC | 7.7% | $13.1m | 999,967 | – | ||
| 4 | ZBIO ZENAS BIOPHARMA INC | 6.9% | $11.7m | 321,983 | – | ||
| 5 | STTK SHATTUCK LABS INC | Healthcare | 6.7% | $11.5m | 3,149,907 | – | |
| 6 | VSTM VERASTEM INC | Healthcare | 5.9% | $10.1m | 1,307,330 | – | |
| 7 | PVLA PALVELLA THERAPEUTICS INC NE | 5.1% | $8.7m | 82,686 | – | ||
| 8 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.8% | $8.2m | 183,704 | – | |
| 9 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 4.2% | $7.2m | 67,586 | – | |
| 10 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.9% | $6.6m | 94,443 | – | |
| 11 | IVA INVENTIVA SA | 3.5% | $6.0m | 1,298,701 | – | ||
| 12 | CMPX COMPASS THERAPEUTICS INC | 3.5% | $6.0m | 1,114,005 | – | ||
| 13 | CMPS COMPASS PATHWAYS PLC | Healthcare | 3.0% | $5.2m | 752,631 | – | |
| 14 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 3.0% | $5.0m | 615,720 | – | |
| 15 | CBIO CRESCENT BIOPHARMA INC. | 2.6% | $4.4m | 372,856 | – | ||
| 16 | PCVX VAXCYTE INC | Healthcare | 2.6% | $4.4m | 95,485 | – | |
| 17 | EVMN EVOMMUNE INC | 2.3% | $3.9m | 228,286 | – | ||
| 18 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.0% | $3.4m | 95,819 | – | |
| 19 | IRON DISC MEDICINE INC | Healthcare | 2.0% | $3.4m | 42,778 | – | |
| 20 | OCULIS HOLDING AG | 1.8% | $3.0m | 149,750 | – | ||
| 21 | ZLAB ZAI LAB LTD | Healthcare | 1.7% | $2.9m | 163,362 | – | |
| 22 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.2% | $2.1m | 131,796 | – | ||
| 23 | ACET ADICET BIO INC | 0.8% | $1.3m | 157,827 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.